CANDEL THERAPEUTICS, INC. Operating Lease, Expense
CANDEL THERAPEUTICS, INC. (CADL) reported Operating Lease, Expense of $500 for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-03-30
- CANDEL THERAPEUTICS, INC. operating lease, expense for fiscal 2021 was $500.00, a 99.92% decline from fiscal 2020.
- CANDEL THERAPEUTICS, INC. operating lease, expense for fiscal 2020 was $619.00K.
| Period end | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|
| 2021-12-31 | $500.00 10-K · filed 2023-03-30 | $459.00K 10-K · filed 2022-03-29 |
| 2020-12-31 | $619.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |